Safety and efficacy of thalidomide in patients with myelofibrosis with myeloid metaplasia.
about
Practical management of classical myeloproliferative disorder patients: a clinician's guideIn vitro antiproliferative activity of the farnesyltransferase inhibitor R115777 in hematopoietic progenitors from patients with myelofibrosis with myeloid metaplasia.Thalidomide for the treatment of idiopathic myelofibrosis.Modern management of myelofibrosis.Pomalidomide is active in the treatment of anemia associated with myelofibrosisA phase-2 trial of low-dose pomalidomide in myelofibrosis.Emerging drugs for myelofibrosis.Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial.Modest activity of pomalidomide in patients with myelofibrosis and significant anemiaChoosing between stem cell therapy and drugs in myelofibrosis.Profile of pomalidomide and its potential in the treatment of myelofibrosis.Tetraspanin CD9 participates in dysmegakaryopoiesis and stromal interactions in primary myelofibrosis.Angiogenesis and anti-angiogenic therapy in myelofibrosis with myeloid metaplasia.Therapeutic renaissance of thalidomide in the treatment of haematological malignancies.Emerging drugs for the therapy of primary and post essential thrombocythemia, post polycythemia vera myelofibrosis.Immunotherapy based approaches in myelofibrosis.Primary myelofibrosis: current therapeutic options.Lenalidomide and prednisone for myelofibrosis: Eastern Cooperative Oncology Group (ECOG) phase 2 trial E4903.Thalidomide treatment in myelofibrosis with myeloid metaplasia.Extremely high levels of von Willebrand factor antigen and of procoagulant factor VIII found in multiple myeloma patients are associated with activity status but not with thalidomide treatment.Sequential combination of thalidomide and erythropoietin determines transfusion independence and disease control in idiopathic myelofibrosis previously insensitive to both drugs used as single agents.Combined treatment with thalidomide, corticosteroids, and erythropoietin in patients with idiopathic myelofibrosis.Efficacy and tolerability of danazol as a treatment for the anaemia of myelofibrosis with myeloid metaplasia: long-term results in 30 patients.Thalidomide plus prednisone with or without danazol therapy in myelofibrosis: a retrospective analysis of incidence and durability of anemia response.
P2860
Q28200207-2875D228-19D6-4AE4-A965-4FAA437B6799Q33348021-B3D6502F-4627-48D4-AFF7-BA352FF2C9ACQ33359542-0F66AAB6-4C26-47BC-947B-648F42037E1CQ33365122-90C7D4C7-78F2-48A2-BC28-28CD4E5A4690Q33385644-FF26EF73-CFAB-4D2A-862F-E3E5E11C89BBQ33392689-B6405619-3688-4C06-A3C1-276792C2EEA6Q33404574-1856A749-12CB-4EDA-A1AD-2FFE3288EF16Q34162867-999D22F4-5612-491E-A4F4-4C45510999D2Q34512203-93812EEB-FA2B-4DE9-B5C2-1353CBE166D1Q34734491-BA770751-1EED-40F1-B4D2-E054305CDFF0Q35427915-AA782AEC-2377-4292-94DA-D3878F0E56E0Q35669864-419460E5-8F78-4AB6-BCF1-9FD21BABACE2Q35994847-86915A3B-DFB0-47A1-A74D-D6D9D3ED42BFQ36171864-401EE332-3AC0-4024-9892-2681269FF221Q37529843-99221F5B-5B1F-4675-87B0-5825A25BA815Q38629189-A3B9479B-0204-4B17-B19A-22240544592DQ41186952-68B443B9-8605-4989-9ED7-EE61FAF6B44EQ41283205-179592CF-96B7-48D9-8B68-FBBD9B5954F6Q43969504-4CFD98C2-00E9-4D3D-B931-EB9E9F8DBBD3Q44518877-CF625436-4E5B-44ED-BC1A-CB9B3A7EC4EEQ44529465-08AA5CE2-A814-483A-A9EC-EFFDD61E8952Q45252410-37973BE8-BEAD-4C82-969E-6E7ECEEDBE39Q46543499-09441C8E-6F43-4B50-8B26-86B824912DD0Q50042813-88DCD5D1-B219-4A5F-8458-8510115AD0F6
P2860
Safety and efficacy of thalidomide in patients with myelofibrosis with myeloid metaplasia.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Safety and efficacy of thalido ...... rosis with myeloid metaplasia.
@ast
Safety and efficacy of thalido ...... rosis with myeloid metaplasia.
@en
Safety and efficacy of thalido ...... rosis with myeloid metaplasia.
@nl
type
label
Safety and efficacy of thalido ...... rosis with myeloid metaplasia.
@ast
Safety and efficacy of thalido ...... rosis with myeloid metaplasia.
@en
Safety and efficacy of thalido ...... rosis with myeloid metaplasia.
@nl
prefLabel
Safety and efficacy of thalido ...... rosis with myeloid metaplasia.
@ast
Safety and efficacy of thalido ...... rosis with myeloid metaplasia.
@en
Safety and efficacy of thalido ...... rosis with myeloid metaplasia.
@nl
P2093
P2860
P1476
Safety and efficacy of thalidomide in patients with myelofibrosis with myeloid metaplasia
@en
P2093
P2860
P356
10.1046/J.1365-2141.2001.02918.X
P407
P577
2001-07-01T00:00:00Z